ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.1_2632
Abstract: Roche, Janssen, Takeda, MSD, Gilead, Bristol Myers Squibb, AstraZenecca; Research Funding: Celgene, Roche, Abbvie; Other Remuneration: Roche, Amgen. Chu, M: Honoraria: AstraZeneca, Gilead, Celgene. Dreyling, M: Honoraria: Bayer, Celgene, Gilead, Janssen, Roche, Acerta, Bayer, Celgene,… read more here.
Keywords: janssen; roche; research funding; celgene ... See more keywords